Generics now dominate the semaglutide market worldwide, pushing brand‑name sales into a more limited niche. Industry trackers note that after a sharp rise in India, sales of generic weight‑loss drugs have slowed and overall demand has levelled off. Recent research finds the drug’s weight‑loss effect varies widely between users, with some seeing robust results and others minimal change. Novo Nordisk announced a partnership with Vivani to create a extended‑release semaglutide implant that could release the drug over a few months. The development aims to give the company a additional option as generic competitors capture more of the market. Analysts say the implant could reshape treatment patterns if clinical trials confirm its safety.